Peri-operative Therapy in Thoracic Cancer
The course presents a review of recent changes in the management of resected NSCLC as well as the management of patients with early stage NSCLC treated with SBRT. The four main topics are:
- Neo-adjuvant and adjuvant immunotherapy
- Adjuvant Targeted therapy
- Post-operative Radiotherapy
- Lung SBRT Distinguishing Progression vs Radiation Fibrosis
Additionally, there is an extra video session on Screening and How Imaging/Staging Availability Affects Survival. It covers the indications, and pitfalls associated with lung cancer screening.
This activity is available from January 31, 2022, through 11:59 p.m. Eastern time on January 30, 2025.
This activity was originally recorded at ASTRO’s Multidisciplinary Thoracic Cancers Symposium, December 2-4th.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, surgeons, nurses, diagnostic radiologists and medical oncologists.
Upon completion of this activity, participants should be able to:
- Discuss adjuvant targeted therapies and immunotherapy.
- Explain the role of post-operative radiation therapy.
- Describe patient management after completion of SBRT.
- Describe the current recommendations for lung cancer screening.
Moderator: Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina
- Catherine Shu, MD, Columbia University, New York and received compensation from AstraZeneca, Genentech, Janssen, Mirati.
- Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina and receives compensation from Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, Regeneron, Advaxis.
- Pamela Samson, MD, MPHS, Washington University School of Medicine, St. Louis and has nothing to disclose.
- Jeremy Brownstein, MD, MS, The Ohio State University, Columbus, Ohio and has nothing to disclose.
- Douglas Arenberg, MD, University of Michigan, Ann Arbor, Michigan and has nothing to disclose.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.